Guidelines on the diagnosis and treatment of active Charcot neuro‐osteoarthropathy in persons with diabetes mellitus (IWGDF 2023)

Author:

Wukich Dane K.1,Schaper Nicolaas C.2,Gooday Catherine3ORCID,Bal Arun4,Bem Robert5,Chhabra Avneesh6,Hastings Mary7,Holmes Crystal8,Petrova Nina L.9,Santini Araujo Maria Gala10ORCID,Senneville Eric11ORCID,Raspovic Katherine M.1ORCID

Affiliation:

1. Department of Orthopaedic Surgery University of Texas Southwestern Medical Center Dallas Texas USA

2. Division of Endocrinology MUMC+, CARIM and CAPHRI Institute Maastricht The Netherlands

3. Elsie Bertram Diabetes Centre Norfolk & Norwich University Hospitals NHS Foundation Trust Norfolk UK

4. Secretary, International Association of Diabetic Foot Surgeons Mumbai India

5. Diabetes Centre Institute for Clinical and Experimental Medicine Prague Czechia

6. Department of Radiology UT Southwestern Medical Center Dallas Texas USA

7. Program in Physical Therapy Washington University School of Medicine St. Louis Missouri USA

8. The Division of Metabolism, Endocrinology and Diabetes The University of Michigan Medical School Ann Arbor Michigan USA

9. Department of Diabetes Diabetic Foot Clinic King's College Hospital NHS Foundation Trust London UK

10. Italian Hospital of Buenos Aires Buenos Aires Argentina

11. Gustave Dron Hospital Univ‐Lille Lille France

Abstract

AbstractThe International Working Group on the Diabetic Foot (IWGDF) has published evidence‐based guidelines on the prevention and management of diabetic foot disease since 1999. This is the first guideline on the diagnosis and treatment of active Charcot neuro‐osteoarthropathy in persons with diabetes published by the IWGDF. We followed the GRADE Methodology to devise clinical questions in the PACO (Population, Assessment, Comparison, Outcome) and PICO (Population, Intervention, Comparison, Outcome) format, conducted a systematic review of the medical literature, and developed recommendations with the rationale. The recommendations are based on the evidence from our systematic review, expert opinion when evidence was not available, and also taking into account weighing of the benefits and harms, patient preferences, feasibility and applicability, and costs related to an intervention. We here present the 2023 Guidelines on the diagnosis and treatment of active Charcot neuro‐osteoarthropathy in persons with diabetes mellitus and also suggest key future topics of research.

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference107 articles.

1. Prevalence of active Charcot disease in the East Midlands of England

2. International Diabetes Foundation.IDF Diabetes Atlas 10th Edition;2021. Accessed 9 August 2022.https://www.diabetesatlas.org

3. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3